Latest VectorY Therapeutics News & Updates

See the latest news and media coverage for VectorY. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
VectorY Therapeutics (VectorY)

Biotechnology company developing vectorized antibody therapies for neurodegenerative diseases

vectorytx.com
Headquarters
Amsterdam, Netherlands
Founded year
2020
Company type
Private company
Number of employees
100–200

Last updated

Latest news about VectorY Therapeutics (VectorY)

In short: VectorY Therapeutics progressed its ALS candidate VTx-002 into Phase 1/2 clinical trials after securing €129 million in Series A funding.

Company announcements

VectorY

VectorY Therapeutics partners with UnLearnAI

They utilize patient-level digital twin technology in the PIONEER-ALS study to enhance development decisions, model disease progression, and reduce timelines and participant burden.

VectorY

VectorY Therapeutics doses first participant in PIONEER-ALS trial

The Phase 1/2 trial evaluates VTx-002, a vectorized antibody targeting TDP-43 in ALS patients. It assesses safety, tolerability, and efficacy across U.S., Europe, and U.K. sites.

Unlock all announcements with a

Media coverage

Morningstar

VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS)

VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) VTx-002 is a first-in-class...

Unlock all articles with a

Never miss news about VectorY

Track VectorY and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

VectorY competitors & trending companies

Browse news for competitors to VectorY and other trending companies.